Valensa’s Chief Science Officer Presents New Research on Efficacy of a Lipidosterolic Extract of Saw Palmetto

In collaboration with Valensa, leading prostate expert Dr. Stephen Strum has published the most comprehensive, global review of clinical studies to evaluate the consumer benefit of  a lipidosterolic extract of Serenoa repens (LSESr), commonly known as saw palmetto.  Through an assessment of 40 years of data Strum’s findings validate the effectiveness of an LSESr like Valensa’s USPlus® […]

Read More »

Valensa CEO Discusses Astaxanthin Market Dynamics in Recent Article

In an interview at the SupplySide West trade show in Las Vegas, Valensa CEO Umasudan (Uma) Pal., noted that while the astaxanthin market has experienced growth over the last decade, “even golden-egg-laying geese can inadvertently be slaughtered.” To learn more about this antioxidant powerhouse, quality and consumer benefits read the entire article.

Read More »